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Urinary excretion of kappa light chains in patients with diabetes
mellitus. The urinary excretion of kappa light chains, f32-microglobulin
and albumin was examined in patients with newly diagnosed and
long-standing insulin-dependent (IDDM) and non-insulin-dependent(NIDDM) diabetes mellitus, and compared to age-matched control
subjects. Patients with IDDM diagnosed within two months, presented
with normal albumin excretion, whereas the concentrations of 132-
microglobulin and kappa light chain in urine were higher than in control
subjects. The initiation of insulin therapy reduced, but did not com-
pletely normalize, the elevated rate of kappa light chain excretion.
Patients with IDDM of long duration showed increased urine excretion
of kappa light chains and albumin. In keeping with the findings in
IDDM, patients with newly diagnosed NIDDM (within one year)
showed increased urinary excretion of kappa light chains compared
with control subjects. There was, however, no further increase in light
chain excretion with longer duration of NIDDM. To study the effect of
short-term hyperglycemia on urinary protein excretion, 12 normal
subjects participated in a three-step hyperglycemic clamp study, during
which their plasma glucose concentration was raised by +50. + 125 and
+300 mgldl. The urine excretion of albumin and /32-microglobulin rose
progressively with each hyperglycemic clamp step, whereas that of
kappa light chain excretion was unaffected by hyperglycemia. We
conclude that increased urinary excretion of kappa light chain is a
consistent finding in all types of diabetes mellitus, and can be observed
even when the albumin excretion is normal. Since the serum concen-
tration of kappa light chain is normal in diabetes, the increased urinary
excretion of kappa light chains must be of renal origin. Although the
underlying mechanism(s) responsible for the kappa light chainuria are
unknown, it cannot be ascribed to the effect of acute hyperglycemia on
glomerular and tubular function.
The appearance of persistent proteinuria (>300 mg/day of
albumin) is considered to represent the clinical hallmark of
diabetic nephropathy [1—4). In the early detection of this
complication, special interest has been focused on microalbu-
minuria, that is, albumin excretion rate (AER) greater than 30
mg/24 hr or 20 g/min [1—21. In addition, we have previously
reported increased excretion of kappa light chains (KLC) in
diabetic patients with proliferative retinopathy but with normal
AER [51.
KLC is a low molecular weight protein, which is thought to
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be freely filtered by the glomerulus and to be nearly completely
reabsorbed (95%) and degraded by the proximal tubule [6, 7].
Consequently, the urinary excretion of KLC is increased in
renal diseases characterized by tubular proteinuria [8, 9] and in
situations where tubular protein reabsorption is impaired [10,
11]. Increased urinary excretion of KLC in a diabetic individual
could, therefore, indicate tubular damage and represent an
important stage in the development of diabetic nephropathy.
The aim of the present study was: 1) to quantitate KLC,
albumin and J32-microglobulin (/32M) excretion in the urine of
patients with insulin-dependent (IDDM) and non-insulin depen-
dent diabetes mellitus (NIDDM), and to correlate protein
excretion rate with the duration of the disease; 2) to prospec-
tively examine the relationship between glycemic control and
urinary protein excretion in patients with newly diagnosed
IDDM; and 3) to examine the effect of short-term graded
hyperglycemia on urinary protein excretion in normal subjects.
Methods
Study A
Urine was collected for 24 hours (in children with newly
diagnosed IDDM 2 x 24 hours; the urines were pooled before
measurement) for determination of albumin, kappa light chains
(KLC), f32-microglobulin (132M) and creatinine clearance from:
(1) 69 patients with new-onset IDDM (within 2 months of
diagnosis); (2) 39 IDDM patients with duration of diabetes
greater than 15 years; (3) 23 patients with new-onset NIDDM
(within one year of diagnosis); and (4) 68 non-insulin dependent
diabetic patients with greater than 10 years duration of their
diabetes (Table 1). The urinary protein excretion was compared
with that of age-matched control subjects. In addition, serum
concentration of KLC was measured in 10 normal subjects (5
females, 5 males; mean age = 41 yrs) and in 8 of the IDD
patients (4 females, 4 males, age = 39 yrs).
Study B
Thirty children (12 females, 18 males) with a mean (± SEM)
ageof 8.6 0.7 years (range 2.1 to 13.7 years) were followed for
two years from the time of diagnosis of diabetes (the first
measurements were made within three days of diagnosis) with
sequential measurements of albumin, KLC and /32Min urine
samples collected during two consecutive days. Urinary protein
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Table 1. Clinical characteristics of patients with newly diagnosed and long standing, insulin dependent (LDDM) and non-insulin dependent
(NIDDM) diabetes mellitus, and in age-matched healthy control subjects
N(F/M)
Age Duration HbA,
%years
Newly diagnosed IDDM 69 (30/39) 9 1 0.2 0.1 12.1 1.5
Control subjects 26(11/15) 11 2 — 6.1 0.3
Long standing IDDM 31 (20/lI) 36 1 23 1 10.0 0.3
Control subjects 15 (10/5) 32 I — 6.2 0.3
Newly diagnosed NIDDM 23 (10/13) 57 1 0.6 0.2 10.6 0.3
Long standing NIDDMb 68 (33/35) 57 2 14 1 11.6 0.3
Control subjects 10 (5/5) 57 2 6.7 0.2
Values are means SEM.
a 16 patients were treated with diet and/or oral hypoglycemic agents; 7 patients were treated with insulin
l, 46 patients were treated with diet and/or oral hypoglycemic agents; 22 patients were treated with insulin
excretion rates were related to glycemic control as estimated by
glycohemoglobin concentrations (HbA1).
Study C
Twelve health subjects (5 females, 7 males) with an age of 28
1 years (range 19 to 40 years) participated in a three-step
hyperglycemic clamp study, during which the plasma glucose
concentration was raised sequentially by +50 mg/dl, + 125
mgldl and + 300 mg/dl [12]. Plasma glucose was determined at
five minute intervals and a variable infusion of 20% dextrose
was adjusted to maintain the plasma glucose concentration at
the desired hyperglycemic level. Each hyperglycemic plateau
lasted for two hours. Timed urine collections for the determi-
nation of glucose, albumin, KLC and f32M concentrations were
obtained immediately before and during each step of the hyper-
glycemic clamp study.
Analytical methods
Plasma and urine glucose concentrations were determined by
the glucose oxidase method on a Beckman Glucose Analyzer II
(Beckman Instruments mc, Fullerton, California, USA). Ali-
quots of neutralized (pH 7.0) urines were stored at —20°C until
analyzed. Concentrations of albumin (Albumin RIA 100, Phar-
macia, Uppsala, Sweden) and f32-microglobulin (Phadebas /32-
microtest, Pharmacia) were measured by specific radioimmu-
noassays [5]. The detection limits of the assays were 0.2
mg/liter and 0.1 mg/liter, respectively. The concentration of free
kappa light chains in urine was measured by immunoturbidom-
etry using antiserum to free kappa light chains (Dako, Copen-
hagen, Denmark) [13]. Kappa light chain isolated from the urine
of a myeloma patient was used as the standard [51. The
detection limit of the assay was 0.5 mg/liter. The serum con-
centration of KLC was measured after gel filtration of the
samples [13]. The detection limit for the serum KLC assay was
0.02 mg/liter. The day-to-day variation in urine albumin, /32-
microglobulin, and KLC excretion was 10 2%, 13 5%, and
9 3% (urine collection from 2 consecutive days in 10 IDDM
subjects). The upper limits of "normal" for the excretion of
albumin, BM and KLC were defined as the mean 2 SD of the
values from control subjects. Glycohemoglobin (HbA1) concen-
tration in blood was measured by cation exchange microcolumn
chromatography (Isolab, Akron, Ohio, USA). Concentrations
of creatinine in serum and urine were measured by routine
methods.
Statistics
All data are expressed as the mean SEM. Analysis of
variance was used to test the significance of differences be-
tween group means (after logarithmic transformation of the
data) and the differences from baseline in Study C. Correlations
were calculated by standard linear regression analysis.
Results
Study A: Urine protein excretion in relation to duration of
disease in IDDM and NIDDM
The patients with new onset IDDM had higher creatinine
clearance values than age matched controls (P < 0.001) (Table
2), indicating an increased glomerular filtration rate (GFR) and
hyperfiltration. In newly diagnosed IDD subjects the rate of
urinary albumin excretion (14 5 vs. 11 4 mg124 hrs) was
similar to controls (Fig. 1). In contrast, the rates of /32-
microglobulin (738 165 vs. 178 57 g/24 hrs; P < 0.01) and
kappa light chain excretion (8.2 1.5 vs. 1.5 0.4 mg/24 hrs;
P < 0.05) were significantly elevated in the new-onset IDD
group. This difference was independent of whether protein
excretion was expressed as absolute values (Fig. 1) or corrected
for glomerular filtration rate (Table 2). The creatinine clearance
was significantly greater in patients with long standing IDDM
compared to their age matched controls (P < 0.01), but was
reduced compared to newly diagnosed IDDM (P < 0.01). In
patients with long standing IDDM the rate of urinary albumin
excretion was elevated compared to age matched controls (42
11 vs. 8 2 mg/24 hrs; P < 0.01) and was threefold greater than
in newly diagnosed IDD patients (Table 2, Fig. 1). No increase
in BM was observed in the long standing IDD subjects (Table 2,
Fig. 2). In contrast, KLC excretion (49.4 5.2 mg/24 hrs) was
increased sixfold compared to the newly diagnosed IDD and
was 16-fold greater than in the age matched controls (Table 2,
Fig. 3). In order to test the possibility, whether the increased
KLC excretion in urine was due to increased production or to
enhanced excretion, serum KLC concentration was measured
in 10 control and 8 IDD subjects. The serum KLC concentra-
tion was similar in controls and IDD's (15.0 1.9 vs. 14.2 1.9
mg/liter), despite significantly higher urinary KLC concentra-
tion in diabetics than in controls (12.8 3.6 vs. 2.1 0.6 mg124
hrs; P < 0.01). There was no significant correlation between the
KLC concentration in serum and urine (r = 0.24; P = NS).
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Table 2. The urinary excretion of albumin, /32-microglobulin (/32m), and kappa light chains (KLC) expressed per glomerular filtration rate (mg
or g/hrs 100 ml of creatinine clearance) in patients with newly diagnosed, long standing IDDM and NIDDM, and in age-matched
control subjects
Creatinine
clearance
Urinary excretion of
Albumin 32m KLC
N mi/mm 1.73 m2 mg ,g mg
New IDDM 69 142 6 9 4 519 116C 6 I"
Controls 26 98 19C II 4 182 58 2 I
LongstandinglDDM 31 1185b 38± 10" 116±18 445C
Controls 15 97 5 8 2 104 54 3 1
New NIDDM 23 104 5 10 4 103 39 7 a
Long standing NIDDM 68 101 5 54 26 132 42 7 IC
Controls 10 106 5 2 1 29 7 2 1
Values are mean SEM.
a P < 0.05, b P < 0.01, C P> 0.001, compared with age-matched control subjects
Creatinine clearance did not differ between patients with new
onset and long standing NIDDM and age-matched control
subjects (Table 2). In new onset NIDD individuals neither the
rates of urinary albumin or BM excretion were elevated (Table
2, Figs. 1 and 2). In contrast, KLC excretion was significantly
increased (7.2 1.2 vs. 1.5 0.5 mg/24 hrs; P < 0.05). In long
standing NIDD subjects urine, albumin excretion (55 26
mg/24 hrs) was significantly increased compared to controls and
the rate of albuminuria was similar to that observed in long
standing IDD (42 11 mg/24 hrs). /32M was slightly elevated in
long standing NIDDM, but this was more a reflection of the
lower rate of f32M excretion in the controls rather than to an
absolute increased rate of f32M excretion in the NIDD group.
KLC excretion remained elevated in the long standing NIDD
group (Table 2, Fig. 1). In NIDDM patients there appeared to
be a segregation of patients in those with normal and elevated
(> 10 mg/24 hr) KLC excretion. Age, duration of diabetes,
HbA, or creatjnine clearance values did not differ between
those with normal and elevated KLC. Of 15 patients with
enhanced KLC excretion, only five had enhanced AER (over 30
mg124 hr).
In both new onset IDD and NIDD subjects there was a strong
positive correlation between rates of /32M and KLC excretion (r
= 0.77 and r = 0.73; P < 0.001); this correlation was not
observed in patients with diabetes of long duration (Table 3).
The rate of KLC excretion was positively correlated with the
rate of albumin excretion in both new onset (r = 0.54; P <
0.001) and long standing IDDM (r = 0.46; P < 0.01). There was
no correlation between the rates of albumin! f32M! KLC excre-
tion and creatinine clearance in any group.
Study B: Relationship between change in urinary protein
excretion and glycemic control
At the time of diagnosis of IDDM, the HbA, concentration
was clearly elevated (13.9 0.5%) in IDD subjects and de-
creased after starting insulin therapy to a nadir of 9.1 0.3%
after one year (Fig. 2). At the end of the 24 month follow-up
period the glycohemoglobin level was 9.8 0.4%. Albumin
excretion was increased at diagnosis (15 3 mg/24 hrs), but was
normalized within two weeks after starting insulin therapy (6
1 mg/24 hrs; P < 0.01 compared with baseline). Thereafter,
albumin excretion remained within the normal range during the
entire 24 month follow-up period. f32M excretion was markedly
elevated during the first days of diagnosis of diabetes (1134
369 sg/24 hr) but was normal one year after diagnosis (160 48
sg/24 hrs; P < 0.05 compared with baseline). At the time of
diagnosis the KLC excretion (7.5 1.6 mg/24 hrs) was elevated
but fell significantly within two weeks after starting insulin
therapy (2.7 0.4 mg/24 hr; P < 0.01 compared with baseline).
However, the KLC excretion never completely returned to
control levels during the two-year follow-up period. It should be
noted that in study A the first urine was collected within two
months after diagnosis, whereas in study B the first urine was
collected during the first three days after diagnosis, at which
time the patients were markedly hyperglycemic.
At the time of diagnosis there was a weak positive correlation
between HbA1 and 24-hour /32M excretion (r = 0.51; P < 0.02),
whereas neither albumin (r =
—0.02; P = NS) nor KLC
excretion (r = 0.35; P = NS) were related to the degree of
glycemic control.
Study C: Effect of acute hyperglycemia on urinary protein
excretion
There was no significant change in albumin excretion rate
when the plasma glucose concentration was raised by +50 and
+125 mg/dl above the fasting level. However, during the + 300
mg!dl hyperglycemic clamp the urinary albumin excretion rate
increased three-fold above basal values (P <0.01; Fig. 3). p2M
excretion rose progressively during each hyperglycemic step
(Fig. 3); /32M excretion during the + 125 mg!dl and +300 mg!dl
hyperglycemic clamp steps were significantly greater than dur-
ing each preceding hyperglycemic level (P < 0.01). The urinary
excretion of KLC remained unchanged from baseline during
each hyperglycemic clamp step.
Urine glucose excretion during the three hyperglycemic
clamp steps was 2.7 1.8, 9.6 2.1 and 133.9 17.9 mg/mm,
respectively. There was no significant correlation between the
rates of urine glucose excretion and urine albuminlf32M/KLC
excretion during the hyperglycemic clamp studies.
Discussion
The present findings indicate that the excretion of KLC in the
urine of newly diagnosed IDDM is increased five-fold, can be
reduced, although not normalized, with insulin therapy, and
increased with the duration of diabetes. In keeping with the
findings in IDDM, KLC excretion was increased in NIDDM
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Fig. 1. The urinary excretion rates of albumin (mg/24 hrs), $2-micro-
globulin (g/24 hrs) and kappa light chains (mg/24 hrs) in patients with
newly diagnosed and long standing IDDM and NIDDM and in their
age-matched control subjects. The protein excretion rates are shown on
a logarithmic scale. The P value indicates the significance of difference
between the diabetic and control subjects.
patients with short duration of the disease. Unlike IDDM the
urinary excretion of KLC did not increase with duration of
NIDDM. It is, however, difficult to define onset of NIDDM
with accuracy, and it is likely that newly diagnosed NIDD
patients had their disease for some time before they actually
were diagnosed. Our results thus suggest that increased excre-
tion of KLC is a consistent finding in diabetics regardless of
type and duration of the disease. It is noteworthy that increased
excretion of KLC in the present study was observed in patients
with normal urinary excretion of albumin and /32M, indicating
that the renal handling of these proteins must differ in diabetic
individuals.
What mechanism(s) are responsible for the increased urinary
excretion of KLC in diabetes mellitus? The serum concentra-
tion of free kappa chains was similar in control and IDD
subjects, and in the same range as previously reported in
healthy subjects without evidence of malignant immunoglobulin
production [13]. The increased KLC concentration in the urine
of diabetic patients must therefore be of renal origin.
It is well documented that tubulo-interstitial changes occur as
frequently as glomerular involvement in the diabetic kidney [14,
151. Both KLC and /32M are relatively low molecular weight
proteins. /32M has a molecular weight of 11,800 daltons, is freely
permeable at the glomerulus, and is almost completely reab-
sorbed in the proximal tubule [161. Its clearance, therefore, has
been considered to represent a useful measure of tubular
function [16]. KLC is a slightly larger protein with a molecular
weight of 23,000 daltons in its monomeric form. If KLC is freely
filtered by the glomerulus, one would expect the KLC excretion
to be similar to that of f32M. Indeed, the urinary excretion of
KLC correlated positively with that of 2M at the time of
diagnosis in both IDDM and NIDDM. However, in both the
newly diagnosed NIDD and IDD, as well as in the long standing
IDD and NIDD subjects, KLC excretion was increased while
f32M was similar to controls. These findings suggest that either
f32M and KLC are not filtered to the same extent by the
glomerulus or that the tubular handling of KLC and /32M are
different. It is of interest that in both new onset and long
standing IDD and NIDD, KLC and albumin excretions were
positively correlated.
Since an elevated plasma glucose concentration represents a
major difference between diabetic and non-diabetic individuals,
we considered whether the increased urinary KLC excretion in
diabetic patients was in some way related to the hyperglycemia.
At the time of diagnosis KLC excretion did not significantly
correlate with the glycosylated hemoglobin level in either IDD
or NIDD. In contrast to KLC excretion, J32M did show a
positive correlation with the HbA1 concentration, suggesting
that hyperglycemia present at diagnosis of IDDM may interfere
with renal handling of /32M. There are several mechanisms by
which hyperglycemia could affect glomerular filtration and/or
the tubular reabsorption of protein. Moderate hyperglycemia,
achieved by an intravenous infusion of glucose, has been shown
to increase the glomerular filtration rate (GFR) in normal
subjects [171. Furthermore, glucose-induced osmotic diuresis
could impair tubular reabsorption of proteins. Both mecha-
nisms could lead to an increase in urinary protein excretion. It
has previously been shown that during an oral glucose load,
resulting in peak plasma glucose concentrations of 400 mg/dl,
there was no significant change in albumin or 132M excretion in
diabetic subjects [18]. Normal subjects, on the other hand,
demonstrated increased albumin excretion while the /32M ex-
cretion was unchanged. In order to examine the effect of acute
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Fig. 3. The urinary excretion rate of albumin, 132-microglobulin and kappa light chains before and after each 2-hour hyperglycemic clamp step
(+50, +125 and +300 mg/dl) in 12 healthy subjects. p < 0.01 indicates significance of difference from baseline value.
hyperglycemia on renal protein excretion we created graded
increase in the plasma glucose concentration using the hyper-
glycemic clamp in a group of normal subjects. As the plasma
glucose concentration was increased to + 125 and +300 mg/dl,
there was a progressive, dose-related rise in /32M. At the highest
hyperglycemic plateau a significant increase in urinary albumin
excretion rate also was observed (Fig. 3). These results indicate
that short term, acute hyperglycemia can affect both glomerular
and/or tubular handling of proteins. KLC excretion, on the
other hand, remained unchanged during the hyperglycemic
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Table 3. Simple correlation coefficients between urinary excretion of
albumin, l32-microglobulin (f32m), kappa light chains (KLC) and
creatinine clearance in patients with newly onset and long standing
IDDM and NIDDM.
New onset IDDM Long standing IDDM
Albumin and /32m 0.05 0.35
Albumin and KLC 0.54c 046b
KLC and /32m 0.73c 0.21
New onset NIDDM Long standing NIDDM
Albumin and /32m 0.25 0.19
Albumin and KLC 0.31 O.44c
KLC and /32m 0.77a 0.08
In conclusion, our data suggest that increased urinary excre-
tion of kappa light chains is a consistent finding in both IDDM
and NIDDM. The excretion of KLC is increased at the time of
diagnosis in IDDM, and its excretion increases further with the
duration of diabetes. The mechanism(s) responsible for the
increased KLC excretion in diabetic individuals remains uncer-
tain at present. A direct effect of hyperglycemia on glomerular
and tubular function is, however, an unlikely explanation.
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clamp. It seems unlikely, therefore, that the enhanced KLC
excretion observed in diabetic patients can be explained by the
effect of short term hyperglycemia on glomerular and/or tubular
function. In keeping with previous reports [18, 19] we could not
demonstrate any correlation between glucosuria and urinary
protein excretion. Other mechanisms must therefore be respon-
sible for the increased KLC excretion in diabetic patients.
Non-enzymatic glycation is a consistent finding in diabetes
and glycation of light chains has been reported in diabetic
patients [20, 21]. It is possible, therefore, that the increased
KLC concentration in the urine of patients with diabetes
represents glycated, rather than nature KLC. Glycation of KLC
could interfere with the normal renal tubular reabsorptive
processes. Light chains with a high isoelectric point and low
electrophoretic motility have been ascribed an increased affinity
for renal tubular cells [22—241. Alternatively, it is known that
after glycation the light chains tend to aggregate into high
molecular weight polymers, and this could alter their handling
by the kidney. Preliminary data from our laboratory suggest
that the isoelectric point of KLC excreted in the urine of
patients with long standing IDDM is increased and the electro-
phoretic mobility decreased.
